NCT05615636 2026-03-16A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLM.D. Anderson Cancer CenterPhase 2 Recruiting36 enrolled
NCT06723457 2026-02-17Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell LymphomaNorthwestern UniversityPhase 2 Active not recruiting34 enrolled